Analysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Target Price at $49.33
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last […]
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last […]
